Last updated: September 8, 2026
The combination of norepinephrine bitartrate, procaine hydrochloride, and propoxycaine hydrochloride is a legacy local-anesthetic product rather than an active growth-market pharmaceutical. Its commercial position is constrained by discontinued or limited marketing, obsolete anesthetic components, weak current clinical demand, and competition from lidocaine- and articaine-based dental products. No reliable current revenue series or public company-specific sales data is available for this exact combination.
What drug contains norepinephrine bitartrate, procaine hydrochloride, and propoxycaine hydrochloride?
The combination is associated with older dental local-anesthetic formulations. Procaine and propoxycaine provide local anesthesia, while norepinephrine bitartrate functions as a vasoconstrictor intended to prolong local anesthetic activity and reduce systemic absorption.
| Component |
Pharmacologic role |
Current commercial relevance |
| Procaine hydrochloride |
Ester local anesthetic |
Largely displaced by amide anesthetics such as lidocaine |
| Propoxycaine hydrochloride |
Potent ester local anesthetic |
Legacy ingredient with little modern dental use |
| Norepinephrine bitartrate |
Vasoconstrictor |
More commonly replaced by epinephrine in dental formulations |
The formulation belongs to an older generation of dental anesthetics that preceded the current dominance of lidocaine, mepivacaine, prilocaine, and articaine products. Propoxycaine has particularly limited present-day relevance because of safety, tolerability, and market-availability concerns.
The exact commercial identity, current sponsor, and active National Drug Code cannot be established reliably from the ingredient description alone. Historical labeling and drug-reference records identify the combination as a legacy dental anesthetic formulation rather than a currently expanding branded product.[1]
What is the current FDA regulatory status?
The combination does not have the profile of an actively marketed FDA product with meaningful current prescription volume. FDA regulatory status for older anesthetic combinations can be difficult to interpret because a product may remain in historical labeling databases after commercial discontinuation.
The relevant regulatory indicators are:
| Regulatory issue |
Assessment |
| FDA-approved active product |
No clearly identifiable currently marketed product based solely on the ingredient combination |
| FDA Orange Book presence |
No established current Orange Book-listed reference product identified for the combination |
| NDA exclusivity |
No current meaningful exclusivity period identified |
| ANDA substitution |
Limited practical relevance without an active reference product |
| OTC status |
Not an OTC growth product |
| Biosimilar pathway |
Not applicable |
| Compounding interest |
Possible in theory, but limited by ingredient availability and clinical demand |
FDA’s Orange Book is principally relevant to approved prescription and certain nonprescription products with therapeutic-equivalence listings. A legacy combination without an active reference product does not create the same generic-entry framework as a currently marketed branded drug.[2]
Does the product have Orange Book patents?
No material Orange Book patent estate is identifiable for this legacy combination. The likely commercial barriers are regulatory and manufacturing-related rather than patent-based.
Any historical patents covering the composition, cartridge, packaging, or manufacturing process would likely have expired decades ago. The absence of active patent protection does not guarantee generic availability. A manufacturer would still need a viable regulatory pathway, source qualified active ingredients, establish stability, validate sterility where applicable, and demonstrate commercial demand.
When does this drug lose exclusivity?
The combination has effectively lost conventional exclusivity. Any original composition, formulation, or process patents would be expected to have expired long before the present period.
A practical exclusivity timeline is:
| Exclusivity category |
Expected status |
| Composition-of-matter patent |
Expired |
| Formulation patent |
Expired or commercially irrelevant |
| Manufacturing patent |
Expired or commercially irrelevant |
| Regulatory exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Market exclusivity from brand loyalty |
Minimal |
The product’s commercial decline therefore does not reflect an impending patent cliff. It reflects therapeutic substitution and product obsolescence.
How large is the market for this anesthetic combination?
The addressable market is effectively niche or inactive. Demand for the individual ingredients exists in limited historical or specialized contexts, but that demand does not translate into a meaningful market for the three-ingredient combination.
Dental anesthetic substitution
Modern dental practice generally relies on:
- Lidocaine with epinephrine
- Articaine with epinephrine
- Mepivacaine, with or without vasoconstrictor
- Prilocaine with felypressin in selected markets
- Bupivacaine for longer-duration anesthesia
These products benefit from greater clinician familiarity, broader supplier availability, stronger contemporary clinical evidence, and more standardized cartridge systems.
The combination of procaine and propoxycaine is disadvantaged because both are ester anesthetics. Ester anesthetics have been displaced in many settings by amide anesthetics, which generally provide more predictable clinical performance and lower concern regarding plasma cholinesterase-related metabolism.
Vasoconstrictor substitution
Norepinephrine is also commercially disadvantaged relative to epinephrine in dentistry. Epinephrine is the standard vasoconstrictor in many dental cartridges. The clinical and procurement infrastructure surrounding epinephrine-containing products is substantially stronger.
What are the principal market dynamics?
Therapeutic obsolescence
The largest demand driver is negative: clinicians have moved away from this ingredient combination. The transition to lidocaine and articaine products reduces the probability that a manufacturer would reintroduce the formulation.
Limited supplier base
Legacy active pharmaceutical ingredients such as propoxycaine hydrochloride may have few qualified suppliers. Low production volumes increase sourcing costs, complicate quality control, and create vulnerability to supply interruptions.
Regulatory reactivation cost
A company seeking to commercialize the combination would need to determine the appropriate FDA pathway. Depending on the product’s regulatory history, this could involve an abbreviated application, a suitability petition, or a full application with substantial bridging and quality documentation.
The cost of reactivating a low-demand injectable or dental cartridge product can exceed the commercial value of the addressable market. Sterility, container closure, extractables and leachables, stability, and manufacturing validation would add cost beyond the active ingredients themselves.
Procurement concentration
Dental anesthetic purchasing is concentrated among established suppliers and distributors. These companies already offer products with stronger demand and simpler commercial messaging. A legacy three-ingredient product would face unfavorable manufacturing economics and limited formulary leverage.
Safety and labeling constraints
The product would require updated evaluation of:
- Cardiovascular effects from norepinephrine
- Hypersensitivity risk associated with ester anesthetics
- Dose-related systemic toxicity
- Drug-interaction warnings
- Use in patients with cardiovascular disease
- Pediatric dosing
- Pregnancy and lactation labeling
- Cartridge or vial administration requirements
Modern regulatory review could expose labeling limitations that did not materially constrain the product when it was originally marketed.
What is the financial trajectory of the product?
The financial trajectory is best characterized as historical decline followed by negligible or unmeasurable current revenue.
| Period |
Commercial trajectory |
| Early market period |
Established use in legacy dental anesthesia |
| Mid-market period |
Declining demand as lidocaine and other amide anesthetics expanded |
| Late market period |
Reduced distribution and potential discontinuation |
| Current period |
No reliable evidence of material branded sales |
| Forward outlook |
Low probability of commercial revival without a specialized institutional or historical-use niche |
No public issuer appears to report revenue separately for this exact combination. It is unlikely to contribute materially to the financial results of a diversified pharmaceutical or dental-products company.
A reasonable financial assessment is:
- Historical revenue was likely generated through dental supply channels rather than large retail pharmacy channels.
- Product-level revenue probably declined as newer anesthetics gained clinical acceptance.
- Current revenue, if any, is likely too small to be separately disclosed.
- Reintroduction would require disproportionate regulatory and manufacturing investment.
- Commercial success would depend on a narrow supply shortage or specialized demand rather than ordinary market growth.
Are there generic-entry opportunities?
Generic entry is technically possible but commercially unattractive.
What would a generic manufacturer need?
A potential manufacturer would need to address:
- Active ingredient qualification for all three components
- Finished-product equivalence
- Stability and shelf-life data
- Sterile manufacturing if supplied as an injectable or cartridge
- Container-closure compatibility
- Dose uniformity
- Preservative or antimicrobial strategy, if applicable
- Labeling and clinical-use justification
- Distribution economics
The lack of an active reference product may make a conventional ANDA strategy difficult. If the historical product cannot be linked to a currently approved reference listing, a sponsor may need to pursue a more burdensome regulatory route.
Would Paragraph IV litigation be likely?
No. There is no meaningful current patent dispute or active Orange Book patent challenge associated with this combination. A Paragraph IV certification requires a listed patent tied to a reference drug. The legacy status of the product means patent litigation is unlikely to be a relevant commercial factor.
What patent protection covers the formulation?
No active formulation or method-of-use patent estate has been identified for the combination.
Potential historical IP categories would have included:
- Multi-ingredient local-anesthetic compositions
- Vasoconstrictor-containing anesthetic mixtures
- Dental cartridge packaging
- Sterile filling processes
- Concentration and stability controls
- Administration devices
Those rights would ordinarily have expired after the applicable patent term. Any remaining manufacturing know-how would be difficult to monetize because the underlying formulation lacks strong current demand.
The practical IP position is therefore:
| IP category |
Current commercial value |
| Composition patent |
None expected |
| Formulation patent |
None expected |
| Method-of-use patent |
None expected |
| Device patent |
Potentially historical only |
| Trade secret |
Limited and nonexclusive |
| Regulatory exclusivity |
None identified |
Which companies are challenging or competing with the product?
No active challenger litigation is apparent. Competition comes from therapeutic substitutes rather than formal patent challengers.
The relevant competitive set includes manufacturers of:
- Lidocaine with epinephrine dental cartridges
- Articaine with epinephrine
- Mepivacaine dental injections
- Prilocaine-based dental anesthetics
- Bupivacaine products for prolonged anesthesia
Major dental-anesthetic suppliers have stronger commercial positions because they operate established cartridge, vial, and dental-distribution platforms. Examples in the broader category have included Dentsply Sirona, Septodont, Pierrel, Hikma, Fresenius Kabi, and other regional injectable-anesthetic suppliers. Their relevance is category-based; it does not establish that any one company currently markets the legacy three-ingredient combination.
What manufacturing and intellectual-property barriers exist?
The principal barriers are operational, not patent-related.
Active ingredient availability
Propoxycaine hydrochloride may be difficult to source at commercial scale. Low-volume production can result in high minimum order quantities, limited qualified manufacturers, and extended quality-assurance timelines.
Sterile production
If the product is supplied in injectable form, sterile manufacturing capacity is required. Dental cartridges require specialized filling and sealing equipment, validated sterilization controls, and high-volume packaging economics.
Analytical testing
The manufacturer would need validated methods for assay, impurities, degradation products, content uniformity, and extractables. A three-active formulation increases analytical complexity compared with a single-agent product.
Distribution economics
Dental anesthetic products are price-sensitive and purchased through established distributors. A low-volume legacy product would have limited leverage over wholesalers and could face unfavorable logistics costs.
How does this combination compare with lidocaine and articaine products?
| Factor |
Norepinephrine/procaine/propoxycaine |
Lidocaine with epinephrine |
Articaine with epinephrine |
| Current clinical use |
Very limited or historical |
Broad |
Broad in dentistry |
| Anesthetic class |
Ester combination |
Amide |
Amide |
| Vasoconstrictor |
Norepinephrine |
Epinephrine |
Epinephrine |
| Supplier availability |
Limited |
Strong |
Strong |
| Regulatory clarity |
Potentially historical |
Established |
Established |
| Generic competition |
Limited practical activity |
Active |
Active or regional |
| Patent relevance |
Minimal |
Product-specific and often expired or limited |
Product-specific |
| Commercial outlook |
Declining or inactive |
Stable mature market |
Strong dental category position |
Lidocaine and articaine have superior commercial infrastructure, stronger clinician adoption, and better manufacturing scale. The legacy combination has no obvious economic advantage that would reverse this substitution pattern.
What generic launch scenarios are realistic?
Three scenarios are plausible:
No launch
This is the most likely outcome. The market may be too small to support regulatory and manufacturing investment.
Contract or specialty relaunch
A specialty manufacturer could reintroduce the product for a defined institutional, historical, or regional customer base. Such a launch would likely be low volume and dependent on advance purchasing commitments.
Shortage-driven reactivation
A temporary shortage of mainstream dental anesthetics could create limited interest in alternative legacy formulations. This would be a supply-response opportunity, not a durable growth strategy.
A broad commercial launch against lidocaine and articaine would face weak demand and unfavorable economics.
What is the geographic coverage?
The product’s present geographic coverage appears limited. Historical availability may have varied by country because local anesthetic registrations, dental practice standards, and controlled-substance rules differ across jurisdictions.
A current multinational opportunity is unlikely because:
- The formulation is not aligned with dominant dental-anesthetic standards.
- Propoxycaine availability may be restricted.
- Regulatory dossiers would need to be rebuilt or updated by jurisdiction.
- Local competitors already supply established alternatives.
- Small markets would not support separate registrations and pharmacovigilance programs.
Any remaining opportunity would most likely be regional rather than global.
What licensing deals or partnerships involve the product?
No current material licensing deal, acquisition, or strategic partnership has been identified for the exact combination. The product is not associated with a visible platform transaction or an active specialty-pharma commercialization program.
A licensing transaction would be difficult to justify unless it included:
- An existing approved dossier
- Active manufacturing capacity
- A protected customer base
- Documented shortage demand
- A profitable regional market
- Transferable cartridge or sterile-fill technology
Without those assets, the formulation is unlikely to attract strategic licensing interest.
Key Takeaways
- The combination of norepinephrine bitartrate, procaine hydrochloride, and propoxycaine hydrochloride is a legacy local-anesthetic formulation.
- Its commercial decline reflects therapeutic substitution, not an approaching patent expiration.
- No material current Orange Book patent estate, Paragraph IV challenge, biosimilar risk, or active litigation has been identified.
- Lidocaine-, articaine-, and mepivacaine-based products dominate the relevant dental-anesthetic market.
- Current revenue is not publicly measurable and is likely negligible or zero as a standalone product.
- Generic entry is technically possible but commercially unattractive.
- Manufacturing, active-ingredient sourcing, sterile filling, and regulatory reactivation are more important barriers than intellectual property.
- A relaunch would require a specialty, regional, or shortage-driven commercial rationale.
FAQs
Is norepinephrine bitartrate the same as epinephrine in dental anesthetics?
No. Norepinephrine and epinephrine are different catecholamine vasoconstrictors. Epinephrine is more commonly used in modern dental local-anesthetic cartridges.
Is propoxycaine hydrochloride still widely used?
No. Propoxycaine is a legacy ester local anesthetic with limited contemporary commercial use and substantially lower market relevance than lidocaine or articaine.
Can a pharmacy compound this three-drug anesthetic?
Compounding depends on applicable federal and state rules, ingredient availability, formulation validation, and intended use. A compounded product would not automatically have the regulatory status of an FDA-approved commercial drug.
Is there a biosimilar version of this product?
No. Biosimilar regulation applies to biologic products. This combination consists of small-molecule anesthetic and vasoconstrictor ingredients.
Does this drug have meaningful investment potential?
On available market evidence, no. The product lacks an identifiable growth market, active patent protection, measurable current revenue base, or clear regulatory pathway that would support a conventional pharmaceutical investment thesis.
References
- National Library of Medicine. (n.d.). DailyMed: Drug labels and historical product information. https://dailymed.nlm.nih.gov/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
- U.S. Food and Drug Administration. (n.d.). Drug safety communications and information on local anesthetics. https://www.fda.gov/drugs
- Malamed, S. F. (2020). Handbook of local anesthesia (7th ed.). Elsevier.
